{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:32:05Z","timestamp":1791469925248,"version":"4.3.4"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004553","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000}}],"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tenovus Scotland","award":["S22-27"],"award-info":[{"award-number":["S22-27"]}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T017112\/1"],"award-info":[{"award-number":["MR\/T017112\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The representation of frailty in type 2 diabetes trials is unclear. This study used individual participant data from trials of newer glucose-lowering therapies to quantify frailty and assess the association between frailty and efficacy and adverse events.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and findings<\/jats:title>\n<jats:p>We analysed IPD from 34 trials of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DDP4) inhibitors. Frailty was quantified using a cumulative deficit frailty index (FI). For each trial, we quantified the distribution of frailty; assessed interactions between frailty and treatment efficacy (HbA1c and major adverse cardiovascular events [MACE], pooled using random-effects network meta-analysis); and associations between frailty and withdrawal, adverse events, and hypoglycaemic episodes. Trial participants numbered 25,208. Mean age across the included trials ranged from 53.8 to 74.2 years. Using a cut-off of FI &gt; 0.2 to indicate frailty, median prevalence was 9.5% (IQR 2.4%\u201315.4%). Applying a higher threshold of FI &gt; 0.3, median prevalence was 0.5% (IQR 0.1%\u20131.5%). Prevalence was higher in trials of older people and people with renal impairment however, even in these higher risk populations, people with FI &gt; 0.4 were generally absent. For SGLT2 inhibitors and GLP1 receptor agonists, there was a small attenuation in efficacy on HbA1c with increasing frailty (0.08%-point and 0.14%-point smaller reduction, respectively, per 0.1-point increase in FI), below the level of clinical significance. Findings for the effect of treatment on MACE (and whether this varied by frailty) had high uncertainty, with few events occurring in trial follow-up. A 0.1-point increase in the FI was associated with more all-cause adverse events regardless of treatment allocation (incidence rate ratio, IRR 1.44, 95% CI 1.35\u20131.54, <jats:italic>p<\/jats:italic> &lt; 0.0001), adverse events judged to the possibly or probably related to treatment (1.36, 1.23, to 1.49, <jats:italic>p<\/jats:italic> &lt; 0.0001), serious adverse events (2.09, 1.85, to 2.36, <jats:italic>p<\/jats:italic> &lt; 0.0001), hypoglycaemia (1.21, 1.06, to 1.38, <jats:italic>p<\/jats:italic> = 0.012), baseline risk of MACE (hazard ratio 3.01, 2.48, to 3.67, <jats:italic>p<\/jats:italic> &lt; 0.0001) and with withdrawal from the trial (odds ratio 1.41, 1.27, to 1.57, <jats:italic>p<\/jats:italic> &lt; 0.0001). The main limitation was that the large cardiovascular outcome trials did not include data on functional status and so we were unable to assess frailty in these larger trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Frailty was uncommon in these trials, and participants with a high degree of frailty were rarely included. Frailty is associated very modest attenuation of treatment efficacy for glycaemic outcomes and with greater incidence of both adverse events and MACE independent of treatment allocation. While these findings are compatible with calls to relax HbA1c-based targets in people living with frailty, they also highlight the need for inclusion of people living with frailty in trials. This would require changes to trial processes to facilitate the explicit assessment of frailty and support the participation of people living with frailty. Such changes are important as the absolute balance of risks and benefits remains uncertain among those with higher degrees of frailty, who are largely excluded from trials.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pmed.1004553","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T21:32:51Z","timestamp":1744061571000},"page":"e1004553","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events"],"prefix":"10.1371","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3625-0945","authenticated-orcid":true,"given":"Heather","family":"Wightman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-0237","authenticated-orcid":true,"given":"Elaine","family":"Butterly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3255-3449","authenticated-orcid":true,"given":"Lili","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-6966","authenticated-orcid":true,"given":"Ryan","family":"McChrystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":true,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2672-7841","authenticated-orcid":true,"given":"David","family":"Phillippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-0221","authenticated-orcid":true,"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicky","family":"Welton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-0990","authenticated-orcid":true,"given":"Miles","family":"Witham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-995X","authenticated-orcid":true,"given":"Kenneth","family":"Rockwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5828-3934","authenticated-orcid":true,"given":"Peter","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"1","key":"pmed.1004553.ref001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"MAB Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"issue":"2","key":"pmed.1004553.ref002","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2337\/dc08-1296","article-title":"Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006","volume":"32","author":"CC Cowie","year":"2009","journal-title":"Diabetes Care"},{"issue":"9","key":"pmed.1004553.ref003","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41574-021-00512-2","article-title":"Type 2 diabetes mellitus in older adults: clinical considerations and management","volume":"17","author":"S Bellary","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"10206","key":"pmed.1004553.ref004","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","article-title":"Frailty: implications for clinical practice and public health","volume":"394","author":"EO Hoogendijk","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"pmed.1004553.ref005","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2666-7568(20)30014-3","article-title":"Frailty measurement, prevalence, incidence, and clinical implications in people with diabetes: a systematic review and study-level meta-analysis","volume":"1","author":"P Hanlon","year":"2020","journal-title":"Lancet Healthy Longev"},{"key":"pmed.1004553.ref006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s43856-021-00029-9","article-title":"An analysis of frailty and multimorbidity in 20,566 UK Biobank participants with type 2 diabetes","volume":"1","author":"P Hanlon","year":"2021","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"pmed.1004553.ref007","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14283\/jfa.2017.39","article-title":"An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017","volume":"7","author":"AJ Sinclair","year":"2018","journal-title":"J Frailty Aging"},{"issue":"3","key":"pmed.1004553.ref008","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/dc13-1545","article-title":"Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial","volume":"37","author":"ME Miller","year":"2014","journal-title":"Diabetes Care"},{"key":"pmed.1004553.ref009","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s13300-021-01035-9","article-title":"Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes","volume":"12","author":"WD Strain","year":"2021","journal-title":"Diabetes Ther"},{"issue":"1","key":"pmed.1004553.ref010","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12916-020-01752-1","article-title":"Identifying frailty in trials: an analysis of individual participant data from trials of novel pharmacological interventions","volume":"18","author":"P Hanlon","year":"2020","journal-title":"BMC Med"},{"issue":"5","key":"pmed.1004553.ref011","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/jgs.12215","article-title":"Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus","volume":"61","author":"AJ Cruz-Jentoft","year":"2013","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"pmed.1004553.ref012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1741-6612.2008.00288.x","article-title":"The challenges of clinical trials in the exclusion zone: the case of the frail elderly","volume":"27","author":"I Ridda","year":"2008","journal-title":"Australas J Ageing"},{"issue":"7","key":"pmed.1004553.ref013","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","article-title":"Frailty in relation to the accumulation of deficits","volume":"62","author":"K Rockwood","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"pmed.1004553.ref014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-015-0328-1","article-title":"No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over","volume":"13","author":"J Warwick","year":"2015","journal-title":"BMC Med"},{"issue":"5","key":"pmed.1004553.ref015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/gerona\/glv228","article-title":"Characterizing frailty status in the systolic blood pressure intervention trial","volume":"71","author":"NM Pajewski","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"pmed.1004553.ref016","first-page":"138","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial","volume":"24","author":"JH Butt","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"pmed.1004553.ref017","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jgs.16917","article-title":"Recombinant zoster vaccine is efficacious and safe in frail individuals","volume":"69","author":"D Curran","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"pmed.1004553.ref018","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-023-01260-3","article-title":"Frailty in randomised controlled trials for dementia or mild cognitive impairment measured via the frailty index: prevalence and prediction of serious adverse events and attrition","volume":"15","author":"H Wightman","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"pmed.1004553.ref019","doi-asserted-by":"crossref","first-page":"e014686","DOI":"10.1161\/JAHA.119.014686","article-title":"accumulation of deficits as a key risk factor for cardiovascular morbidity and mortality: a pooled analysis of 154 000 individuals","volume":"9","author":"MA Farooqi","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"pmed.1004553.ref020","doi-asserted-by":"crossref","first-page":"e066491","DOI":"10.1136\/bmjopen-2022-066491","article-title":"Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol","volume":"12","author":"E Butterly","year":"2022","journal-title":"BMJ Open"},{"key":"pmed.1004553.ref021","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"SD Searle","year":"2008","journal-title":"BMC Geriatr"},{"issue":"6","key":"pmed.1004553.ref022","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jrsm.1661","article-title":"Two-stage or not two-stage? That is the question for IPD meta-analysis projects","volume":"14","author":"RD Riley","year":"2023","journal-title":"Res Synth Methods"},{"issue":"12","key":"pmed.1004553.ref023","doi-asserted-by":"crossref","first-page":"afad221","DOI":"10.1093\/ageing\/afad221","article-title":"How to construct a frailty index from an existing dataset in 10 steps","volume":"52","author":"O Theou","year":"2023","journal-title":"Age Ageing"},{"key":"pmed.1004553.ref024","doi-asserted-by":"crossref","unstructured":"Phillippo DM, editor. multinma: An R package for Bayesian network meta-analysis of individual and aggregate data. Evidence Synthesis and Meta-Analysis in R Conference 2021; 2021.","DOI":"10.32614\/CRAN.package.multinma"},{"key":"pmed.1004553.ref025","first-page":"e2427402","article-title":"Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis","author":"P Hanlon","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"pmed.1004553.ref026","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.mad.2006.01.002","article-title":"Limits to deficit accumulation in elderly people","volume":"127","author":"K Rockwood","year":"2006","journal-title":"Mech Ageing Dev"},{"issue":"8","key":"pmed.1004553.ref027","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s43587-021-00099-3","article-title":"The degree of frailty as a translational measure of health in aging","volume":"1","author":"SE Howlett","year":"2021","journal-title":"Nat Aging"},{"issue":"4","key":"pmed.1004553.ref028","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamacardio.2021.4932","article-title":"Practical recommendations on quantifying and interpreting treatment effects in the presence of terminal competing risks: a review","volume":"7","author":"ZR McCaw","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"1","key":"pmed.1004553.ref029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12916-019-1427-1","article-title":"Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis","volume":"17","author":"P Hanlon","year":"2019","journal-title":"BMC Med"},{"key":"pmed.1004553.ref030","article-title":"Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults","author":"M Denkinger","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"pmed.1004553.ref031","doi-asserted-by":"crossref","first-page":"d7995","DOI":"10.1136\/bmj.d7995","article-title":"The idolatry of the surrogate","volume":"343","author":"JS Yudkin","year":"2011","journal-title":"BMJ"},{"key":"pmed.1004553.ref032","doi-asserted-by":"crossref","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Q Shi","year":"2023","journal-title":"BMJ"},{"issue":"12","key":"pmed.1004553.ref033","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2022.06.037","article-title":"Sacubitril\/Valsartan and frailty in patients with heart failure and preserved ejection fraction","volume":"80","author":"JH Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"pmed.1004553.ref034","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction\u00a0: a post hoc analysis of the DAPA-HF trial","volume":"175","author":"JH Butt","year":"2022","journal-title":"Ann Intern Med"},{"issue":"8","key":"pmed.1004553.ref035","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/jgs.16436","article-title":"Changes in predictive performance of a frailty index with availability of clinical domains","volume":"68","author":"SM Shi","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"pmed.1004553.ref036","doi-asserted-by":"crossref","first-page":"M146-56","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"LP Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004553","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T17:54:47Z","timestamp":1746467687000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004553"}},"subtitle":[],"editor":[{"given":"Sanjay","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004553","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pmed.1004553","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}